As the COVID-19 pandemic continues, scientists are making significant headway in understanding the transmission of the SARS-CoV-2 coronavirus and the immune response it triggers at the time of infection. Researchers have provided new data on the very early stages of immune response. ...
The Discovery trial was originally launched in March 2020 by Inserm to evaluate possible treatments for Covid-19. On January 13th, 2021, the Discovery Europe trial Data Safety Monitoring Boards (DSMB) evaluated an interim report based on 776 patients of whom 389 received ...
Des chercheurs ont démontré in vitro le pouvoir anti-infectieux de véritables "leurres biologiques", les vésicules extracellulaires qui portent à leur surface les récepteurs du virus SARS-CoV-2, responsable de la pandémie Covid-19. Ces résultats ouvrent de nouvelles pistes thérapeutiques et poussent les chercheurs ...
So-called "persistent" bacterial infections constitute a major public health problem and are linked to significant failures of antibiotic treatments. Researchers from Inserm and Université de Rennes 1, in collaboration with a team based in Switzerland, have identified a new mechanism to explain ...
La dépression est un trouble mental qui touche plus de 264 millions de personnes de tous âges dans le monde. La compréhension de ces mécanismes est essentielle pour le développement de stratégies thérapeutiques efficaces. Des chercheurs de l’Institut Pasteur, de l’Inserm et ...
Teams from the Pitié-Salpêtrière AP-HP hospital, Sorbonne University, Inserm and the Pasteur Institute have carried out work to study the role that IgA-type antibodies play in the protection of body against Covid-19 in the mucous membranes, in particular respiratory. ...
Press release
14.12.2021
Press release
21.10.2021
06.12.2021
09.12.2021